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Background
The cyclic nucleotides adenosine 3’,5’-cyclic monopho-
sphate (cAMP) and guanosine 3’,5’-cyclic monopho-
sphate (cGMP) are well-known second messengers.
They play an important role in signal transduction.
They control numerous functions ranging from ion
channel opening to regulation of gene expression.
In 1963, cAMP and cGMP were detected in rat urine.
Indeed, this was the first proof of cGMP in biolocigal
systems [1]. In 1984, Newton et al. demonstrated the
possible presence of cytidine 3’,5’-cyclic monophosphate
(cCMP) in various rat tissues [2] and, two years later, of
uridine 3’,5’-cyclic monophosphate (cUMP) [3] by fast
atom bombardment. Furthermore, cCMP was suppo-
sedly detected in urine of patients with acute leukemia
[4,5] by radioimmuno assay. These findings point to a
biological function of cCMP and cUMP. However, due
to significant methodological problems, studies of the
biological function of cCMP und cUMP were no longer
continued.
Recently, we have developed a method based on high-
performance liquid chromatography-coupled mass spec-
trometry (HPLC-MS/MS), which allows the simulta-
neous determination of all cyclic nucleotides (cNMPs).
Using this highly sensitive method we were able to
detect and quantify cAMP, cGMP and cCMP as well as
cUMP in various mammalian cell lines. We have opti-
mized this method for the quantitation of cyclic nucleo-
tides in complex biolocigal matrices, like urine and
organs.
Methods
Nucleotide extraction of cells was performed by treating
cells with a mixture of organic solvents and heating the
samples at 98°C. After centrifugation the supernatant
fluid was evaporated under a nitrogen stream and the
residual pellet was resuspended in water. Detection and
quantitation of cNMPs was achieved by an analytical
method based on HPLC-MS/MS.
To avoid serious matrix effects due to the complex
urine composition we enzymatically synthesized
13C
15N-
labeled internal standards for each cyclic nucleotide.
Urine sample preparation was achieved by treating urine
with acetonitrile containing those standards. The read-
out was performed as described above. The cCMP con-
centration was normalized to mmol creatinine. Creati-
nine concentration in urine was determined by gas
chromatography -MS.
Results and discussion
We could show that, in addition to cAMP and cGMP,
cCMP and cUMP are present in all studied cell lines
(Table 1). Remarkably, the cCMP- and cUMP-contents
in HeLa cells are comparable to the cGMP contents,
and in B103 cells the the cCMP- and cUMP-content is
even two-fold and three-fold higher, respectively.
Moreover, we analyzed human urine from healthy
volunteers for cyclic nucleotides by HPLC-MS/MS. Our
studies revealed that besides cAMP and cGMP, cCMP is
present in human urine.
Conclusion
Our data suggest that cCMP and cUMP play different
roles in the regulation of the function of cell types origi- * Correspondence: burhenne.heike@mh-hannover.de
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unequivocal identification of cCMP in human urine
opens the door for (patho)physiological studies.
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Table 1
cNMP content (pmol/10
6 cells)
Cell type Lineage cAMP cGMP cCMP cUMP
HeLA epithelial cells 2.1 ± 0.5 1.5 ± 0.5 0.3 ± 0.1 0.7 ± 0.3
HL-60 myeloid cells 7.0 ± 1.4 0.3 ± 0.1 0.1 ± 0.03 0.3 ± 0.03
J774 macrophages 11.0 ± 1.6 1.2 ± 0.1 0.5 ± 0.02 1.2 ± 0.1
CHO epithelial cells 33.3 ± 4.0 10.2 ± 1.3 8.0 ± 1.6 6.7 ± 1.8
B103 neuroblastoma cells 55.1 ± 7.3 7.5 ± 0.8 14.4 ± 1.5 22.3 ± 2.8
COS-7 fibroblasts 82.2 ± 11.3 52.1 ± 3.1 16.3 ± 1.7 25.1 ± 2.2
HEK 293 epithelial cells 106.5 ± 11.3 73.3 ± 5.2 32.6 ± 6.2 54.9 ± 11.3
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